

FIGURE 1




FIGURE 2

CDR2

CDR3

YISRGGGIFYYQDSIKG	EKYGKRG	MDY	(J20.8)
VSTS-TV	QKYNKRA	MDY	(F4.1)
AYSLV	TARATWDW	FAY	(F14.6)

FIGURE 3

-

Réponse anti-streptavidine




FIGURE 4A

Réponse anti-peroxydase





FIGURE 4B



PEPTIDE-PL

PL

FIGURE 5







FIGURE 6



Time of transfection (in hours)

FIGURE 7





□ pLK₁₉

□ CW-K₁₉

■ K₁₉-P3

D PEI

FIGURE 8A

FIGURE 8B





FIGURE 9A






FIGURE 9B

ACTIVITE ANTIVIRALE DES ANTICORPS ANTI-ADN




FIGURE 10

FIGURE 11A

TITRES INFECTIEUX AU JOUR 13 Exp III




FIGURE 11B

Titres infectieux au jour 13 Exp V






FIGURE 11C





□ PV1/Mahoney

FIGURE 12




FIGURE 13A

FIGURE 13B




FIGURE 13D




FIGURE 13C